ADC Therapeutics SA (ADCT) Stock Forecast & Price Target
ADC Therapeutics SA · NYSE
$1.11-0.03 (-2.63%)
15-min delayed · Jul 28, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 3 firms covering ADC Therapeutics SA, 1 rate it Buy or better, 2 sit at Hold, and 0 rate it Sell or worse, a hold consensus. The target range is very wide, $2.00 to $10.00 (about 5.0x), which points to deep disagreement over how to value the company rather than near-term timing. The average target of $6.67 sits 501% above the current $1.11. The rating mix has stayed broadly stable, with Buy-side ratings easing from 3 to 1 over recent months. On the fundamentals, the Street sees revenue growth near 0% this year and 68% next, consensus EPS building from about $-0.22 next quarter toward $-0.66 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS3 ratings
Hold
Strong Buy00%
Buy133%
Hold267%
Sell00%
Strong Sell00%
Based on 3 analysts giving stock ratings to ADC Therapeutics SA.
As of Jul, 1 of 3 firms rate ADCT a Buy (2 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
ADCT EPS & revenue forecast
EPS · NEXT QUARTER
$-0.22
Range $-0.27 – $-0.19 · 5 analysts · -28% YoY
Next period, 5 analysts expect ADC Therapeutics SA to earn $-0.22 a share (range $-0.27 – $-0.19), versus $-0.30 a year earlier. Full-year consensus is $-0.86, growing to $-0.66 the year after.
REVENUE · NEXT QUARTER
$19.0M
Range $17.0M – $21.1M · 5 analysts · +17% YoY
Revenue is expected to reach $19.0M (range $17.0M – $21.1M), +17.0% year-over-year. Full-year consensus is $80.9M, rising to $123.8M next year.
Top analysts covering ADC Therapeutics SA
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on ADCT.
#1
Michael Schmidt
Guggenheim · Rank #1
Buy
$10.00+800.9% to target
Overall win rate
55%
+ Follow
#2
Leonid Timashev
RBC Capital · Rank #69
Hold
$2.00+80.2% to target
Overall win rate
42%
+ Follow
#3
Gregory Renza
RBC Capital · Rank #179
Buy
$8.00+620.7% to target
Overall win rate
34%
+ Follow
#4
RB
Robert Burns
HC Wainwright & Co. · Rank #195
Hold
No targeton ADCT
Overall win rate
38%
+ Follow
#5
SL
Sudan Loganathan
Stephens & Co.
Buy
$8.00+620.7% to target
Coverage
—
+ Follow
ADCT stock forecast FAQ
What is ADCT's average 12-month price target?+
The 2 analysts with a live target average $6.67 for ADC Therapeutics SA over the next 12 months, ranging from a $10.00 high to a $2.00 low.
Is ADCT stock a Buy, Sell or Hold right now?+
The current consensus is Hold. Of the 3 analyst ratings, 1 are Buy or Strong Buy, 2 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for ADCT?+
The Street-high target is $10.00 (Guggenheim), and the Street-low is $2.00 (RBC Capital). The average of all 2 active targets is $6.67.
How many Wall Street analysts cover ADCT?+
3 analysts have an active rating on ADC Therapeutics SA, and 2 firms carry a live 12-month price target.
Who is the most accurate analyst covering ADCT?+
Among analysts who currently cover ADCT, Michael Schmidt of Guggenheim has the strongest overall Quantellect track record (Rank #1). Their current call is Buy with a $10.00 target.
What is ADC Therapeutics SA's projected EPS for next quarter?+
The consensus estimate is $-0.22 per share (range $-0.27 – $-0.19) across 5 analysts. Full-year EPS is projected at $-0.86, rising to $-0.66 the following year.
How much revenue is ADC Therapeutics SA expected to report next quarter?+
Consensus revenue is $19.0M (range $17.0M – $21.1M). Full-year revenue is projected at $80.9M, growing to $123.8M next year.
Have analysts been upgrading or downgrading ADCT lately?+
As of Jul, 1 of 3 firms rate ADCT a Buy (2 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their ADCT calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
